An Early Phase 1 interventional study of dual-chamber syringe in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-02.
Sponsored by Pfizer · Early Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Usability testing of the dual-chambered syringe in conjunction with the proposed patient instructions for use.
Usability testing of the dual-chambered syringe in conjunction with the proposed patient instructions for use
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: dual-chamber syringe
dual-chamber syringe for mock injection
Delivery System Success Rate (DSSR)
DSSR was defined as percentage of participants who were able to successfully expel the selected dose from the Caverject Impulse Dual Chamber Delivery System when relying on the modified Instructions for Use (IFU). The process was considered successful if the attempt was observed and documented by study personnel AND the participant didn't receive any operational/"hands on" demonstration on how to operate the plunger from study personnel AND after performing all preparatory steps, the participant was able to expel the dose to the selected plunger stop-point without any unexpected interruption.
Time frame: Day 1
Number of Participants With Categorical Responses to the Participant Assessment Tool (PAT): Instructions Provided Were Useful?
Participant responses were reported as follows: Very Useful, Somewhat Useful, Not Very Useful, Not Useful At All.
Time frame: Day 1
Number of Participants With Categorical Responses to the PAT: Instructions Provided Were Clear?
Participant responses were reported as follows: Very clear, Somewhat clear, Not very clear, Not clear at all.
Time frame: Day 1
Number of Participants With Categorical Responses to the PAT: Most Difficult Step?
Participant responses were reported as follows: No steps really difficult, Attaching needle, Mixing the solution, Getting the air out of syringe, Setting the dose, Pushing plunger, Other.
Time frame: Day 1
Number of Participants With Categorical Responses to the PAT: Syringe Easy to Use?
Participant responses were reported as follows: Very easy, Somewhat easy, Somewhat difficult, Very difficult.
Time frame: Day 1
Number of Participants Providing Responses to Any Question on the PAT
Number of participants providing responses on questions in the PAT. Questions were as follows: What step did you stop? Why?; Instructions provided were useful?; Instructions provided were clear?; Most difficult step?; Syringe easy to use?
Time frame: Day 1
Time Required to Perform Segments 1 to 5
Steps involved while using the Caverject Impulse Delivery System were categorized into segments: Segment 1 (Assembly While Using the Caverject Impulse Delivery System), Segment 2 (Mixing the Solution), Segment 3 (De-aerating the Syring While Using the Caverject Impulse Delivery System), Segment 4 (Setting the Dose) and Segment 5 (Performing the Injection While Using the Caverject Impulse Delivery System).
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q1
OAT, Q1: Participant assembled the components correctly. Observer responses were reported as follows: Yes, No. A "No" answer indicated failure according to the OAT. Q1 and Q2 made up Segment 1: Assembly of Components.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q2
OAT, Q2: Evidence of mechanical malfunction or defect for Segment 1. Observer responses were reported as follows: Yes, No. Q1 and Q2 made up Segment 1: Assembly of Components.
Time frame: Day 1
Number of Participants Whom the Observer Had Categorical Responses to in the OAT: Q3
OAT, Q3: Participant performed mixing step correctly. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q3 to Q5 made up Segment 2: Mixing the Solution.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q4
OAT, Q4: Participant positioned piston correctly. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the SAP. Q3 to Q5 made up Segment 2: Mixing the Solution.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q5
OAT, Q5: Evidence of mechanical malfunction/defect for Segment 2. Observer responses were reported as follows: Yes, No. Q3 to Q5 made up Segment 2: Mixing the Solution.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q6
OAT, Q6: De-aeration step performed successfully. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q7
OAT, Q7: Participant depressed the plunger correctly to de-aerate the syringe. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the SAP. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q8
OAT, Q8: Evidence of mechanical malfunction/defect for Segment 3. Observer responses were reported as follows: Yes, No. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.
Time frame: Day 1
Number of Participants Whom the Observer Had Categorical Responses to in the OAT: Q9
OAT, Q9: Participant was able to set a dose (any dose) for delivery. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q9 and Q10 made up Segment 4: Setting the Dose.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q10
OAT, Q10: Evidence of mechanical malfunction/defect for Segment 4. Observer responses were reported as follows: Yes, No. Q9 and Q10 made up Segment 4: Setting the Dose.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q11
OAT, Q11: Participant successfully set the correct dose (as assigned). Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q12
OAT, Q12: Participant successfully expelled the dose into the target. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q13
OAT, Q13: Was there any difficulty/obstruction encountered in expelling dose? Observer responses were reported as follows: Yes, No. A "Yes" response indicated failure according to the SAP. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q14b
OAT, Q14b: Participant successfully expelled/injected the assigned dose (per Dose Card). Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q16
OAT, Q16: Evidence of mechanical malfunction/defect. Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
Time frame: Day 1
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q17
OAT, Q17: Participant understood reason excess liquid was present after a partial-dose injection. Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
Time frame: Day 1
| Milestone | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DSSR was defined as percentage of participants who were able to successfully expel the selected dose from the Caverject Impulse Dual Chamber Delivery System when relying on the modified Instructions for Use (IFU). The process was considered successful if the attempt was observed and documented by study personnel AND the participant didn't receive any operational/"hands on" demonstration on how to operate the plunger from study personnel AND after performing all preparatory steps, the participant was able to expel the dose to the selected plunger stop-point without any unexpected interruption.
| percentage of participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting | All Participants |
|---|---|---|---|---|---|---|---|---|---|
| Delivery System Success Rate (DSSR) | 66.67 (NA to NA) | 66.67 (NA to NA) | 100.00 (NA to NA) | 100.00 (NA to NA) | 100.00 (NA to NA) | 83.33 (NA to NA) | 100.00 (NA to NA) | 100.00 (NA to NA) | 89.58 (79.34 to 100.0) |
This post-hoc DSSR was calculated in order to provide a DSSR that recognized as a "failure" only those participants who were unable to successfully complete the overall injection task, regardless of whether they met with difficulties at any step.
| percentage of participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting | All Participants |
|---|---|---|---|---|---|---|---|---|---|
| DSSR Based on the Primary Objective | 83.33 (NA to NA) | 83.33 (NA to NA) | 100.00 (NA to NA) | 100.00 (NA to NA) | 100.00 (NA to NA) | 83.33 (NA to NA) | 100.00 (NA to NA) | 100.00 (NA to NA) | 93.75 (84.63 to 100.0) |
Participant responses were reported as follows: Very Useful, Somewhat Useful, Not Very Useful, Not Useful At All.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Very useful | 5 | 5 | 6 | 5 | 6 | 5 | 5 | 6 |
| Somewhat useful | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Not very useful | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Not useful at all | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Missing answer | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Participant responses were reported as follows: Very clear, Somewhat clear, Not very clear, Not clear at all.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Very clear | 5 | 4 | 6 | 6 | 6 | 5 | 5 | 5 |
| Somewhat clear | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 1 |
| Not very clear | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not clear at all | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Missing answer | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Participant responses were reported as follows: No steps really difficult, Attaching needle, Mixing the solution, Getting the air out of syringe, Setting the dose, Pushing plunger, Other.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| No steps really difficult | 5 | 3 | 4 | 5 | 6 | 4 | 5 | 5 |
| Attaching needle | 0 | 1 | 2 | 1 | 0 | 2 | 0 | 0 |
| Mixing the solution | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Getting the air out of syringe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Setting the dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Pushing plunger | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Other | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Missing answer | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Participant responses were reported as follows: Very easy, Somewhat easy, Somewhat difficult, Very difficult.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Very easy | 4 | 3 | 5 | 6 | 6 | 5 | 6 | 6 |
| Somewhat easy | 1 | 3 | 1 | 0 | 0 | 1 | 0 | 0 |
| Somewhat difficult | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Very difficult | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Missing answer | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants providing responses on questions in the PAT. Questions were as follows: What step did you stop? Why?; Instructions provided were useful?; Instructions provided were clear?; Most difficult step?; Syringe easy to use?
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| What step did you stop? Why? | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Instructions provided were useful? | 5 | 6 | 6 | 6 | 6 | 6 | 5 | 6 |
| Instructions provided were clear? | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Most difficult step? | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Syringe easy to use? | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Steps involved while using the Caverject Impulse Delivery System were categorized into segments: Segment 1 (Assembly While Using the Caverject Impulse Delivery System), Segment 2 (Mixing the Solution), Segment 3 (De-aerating the Syring While Using the Caverject Impulse Delivery System), Segment 4 (Setting the Dose) and Segment 5 (Performing the Injection While Using the Caverject Impulse Delivery System).
| seconds | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Segment 1 (n = 6, 6, 6, 6, 6, 6, 6, 6) | 148.8 ± 37.20 | 189.3 ± 140.13 | 176.0 ± 72.92 | 194.3 ± 107.53 | 246.5 ± 131.85 | 168.2 ± 82.76 | 142.3 ± 105.78 | 144.5 ± 23.35 |
| Segment 2 (n = 5, 6, 6, 6, 6, 5, 6, 6) | 47.2 ± 21.53 | 73.0 ± 63.11 | 42.3 ± 14.19 | 53.8 ± 30.73 | 53.8 ± 21.68 | 50.2 ± 35.90 | 64.2 ± 50.03 | 39.5 ± 13.92 |
| Segment 3 (n = 5, 6, 6, 6, 6, 5, 6, 6) | 49.2 ± 15.69 | 60.2 ± 40.41 | 71.8 ± 22.69 | 79.5 ± 89.17 | 55.8 ± 32.03 | 42.6 ± 5.86 | 43.2 ± 22.13 | 63.3 ± 24.82 |
| Segment 4 (n = 5, 5, 6, 6, 6, 5, 6, 6) | 34.4 ± 29.55 | 37.4 ± 59.77 | 29.0 ± 23.08 | 30.0 ± 26.71 | 20.0 ± 13.07 | 8.4 ± 6.31 | 31.7 ± 24.20 | 35.7 ± 16.50 |
| Segment 5 (n = 5, 5, 6, 6, 6, 5, 6, 6) | 30.4 ± 17.04 | 38.8 ± 53.64 | 30.3 ± 17.77 | 19.2 ± 11.96 | 30.8 ± 15.25 | 17.4 ± 13.24 | 27.3 ± 20.38 | 30.8 ± 17.51 |
OAT, Q1: Participant assembled the components correctly. Observer responses were reported as follows: Yes, No. A "No" answer indicated failure according to the OAT. Q1 and Q2 made up Segment 1: Assembly of Components.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 5 | 6 | 6 | 6 | 6 | 5 | 6 | 6 |
| No (FAIL per OAT) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q2: Evidence of mechanical malfunction or defect for Segment 1. Observer responses were reported as follows: Yes, No. Q1 and Q2 made up Segment 1: Assembly of Components.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Excluded from Q2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OAT, Q3: Participant performed mixing step correctly. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q3 to Q5 made up Segment 2: Mixing the Solution.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 5 | 6 | 6 | 6 | 6 | 5 | 6 | 6 |
| No (FAIL per OAT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did not participate | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q4: Participant positioned piston correctly. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the SAP. Q3 to Q5 made up Segment 2: Mixing the Solution.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 5 | 6 | 6 | 6 | 6 | 5 | 6 | 6 |
| No (FAIL per SAP) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did not participate | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q5: Evidence of mechanical malfunction/defect for Segment 2. Observer responses were reported as follows: Yes, No. Q3 to Q5 made up Segment 2: Mixing the Solution.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No | 5 | 6 | 6 | 6 | 6 | 5 | 6 | 6 |
| Did not participate | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q6: De-aeration step performed successfully. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 5 | 5 | 6 | 6 | 6 | 5 | 6 | 6 |
| No (FAIL per OAT) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did not participate | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q7: Participant depressed the plunger correctly to de-aerate the syringe. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the SAP. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 5 | 5 | 6 | 6 | 6 | 5 | 6 | 6 |
| No (FAIL per SAP) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did not participate | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q8: Evidence of mechanical malfunction/defect for Segment 3. Observer responses were reported as follows: Yes, No. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No | 5 | 5 | 6 | 6 | 6 | 5 | 6 | 6 |
| Did not participate | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q9: Participant was able to set a dose (any dose) for delivery. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q9 and Q10 made up Segment 4: Setting the Dose.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 5 | 5 | 6 | 6 | 6 | 5 | 6 | 6 |
| No (FAIL per OAT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did not participate | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q10: Evidence of mechanical malfunction/defect for Segment 4. Observer responses were reported as follows: Yes, No. Q9 and Q10 made up Segment 4: Setting the Dose.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No | 5 | 5 | 6 | 6 | 6 | 5 | 6 | 6 |
| Did not participate | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q11: Participant successfully set the correct dose (as assigned). Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 5 | 5 | 6 | 6 | 6 | 5 | 6 | 6 |
| No (FAIL per OAT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did not participate | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q12: Participant successfully expelled the dose into the target. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 5 | 5 | 6 | 6 | 6 | 5 | 6 | 6 |
| No (FAIL per OAT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did not participate | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q13: Was there any difficulty/obstruction encountered in expelling dose? Observer responses were reported as follows: Yes, No. A "Yes" response indicated failure according to the SAP. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes (FAIL per SAP) | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| No | 4 | 4 | 6 | 6 | 6 | 5 | 6 | 6 |
| Did not participate | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q14b: Participant successfully expelled/injected the assigned dose (per Dose Card). Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 5 | 5 | 6 | 6 | 6 | 5 | 6 | 6 |
| No | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did not participate | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q16: Evidence of mechanical malfunction/defect. Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No | 5 | 5 | 6 | 6 | 6 | 5 | 6 | 6 |
| Did not participate | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
OAT, Q17: Participant understood reason excess liquid was present after a partial-dose injection. Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.
| participants | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting |
|---|---|---|---|---|---|---|---|---|
| Yes | 5 | 5 | 6 | 0 | 6 | 5 | 6 | 0 |
| No | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did not participate | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Not applicable (tested full dose) | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 6 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Caverject 10 mcg Device - 2.5 mcg Dose Setting | — | 0/6 (0%) | 0/6 (0%) |
| Caverject 10 mcg Device - 5 mcg Dose Setting | — | 0/6 (0%) | 0/6 (0%) |
| Caverject 10 mcg Device - 7.5 mcg Dose Setting | — | 0/6 (0%) | 0/6 (0%) |
| Caverject 10 mcg Device - 10 mcg Dose Setting | — | 0/6 (0%) | 0/6 (0%) |
| Caverject 20 mcg Device - 5 mcg Dose Setting | — | 0/6 (0%) | 0/6 (0%) |
| Caverject 20 mcg Device - 10 mcg Dose Setting | — | 0/6 (0%) | 0/6 (0%) |
| Caverject 20 mcg Device - 15 mcg Dose Setting | — | 0/6 (0%) | 0/6 (0%) |
| Caverject 20 mcg Device - 20 mcg Dose Setting | — | 0/6 (0%) | 0/6 (0%) |
| Age, Continuous(years) | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 53.0 ± 9.1 | 52.7 ± 10.0 | 51.3 ± 9.0 | 53.5 ± 9.0 | 63.0 ± 2.5 | 55.3 ± 4.8 | 57.8 ± 6.8 | 51.8 ± 5.6 | 54.8 ± 7.9 |
| Sex: Female, Male(Participants) | Caverject 10 mcg Device - 2.5 mcg Dose Setting | Caverject 10 mcg Device - 5 mcg Dose Setting | Caverject 10 mcg Device - 7.5 mcg Dose Setting | Caverject 10 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 5 mcg Dose Setting | Caverject 20 mcg Device - 10 mcg Dose Setting | Caverject 20 mcg Device - 15 mcg Dose Setting | Caverject 20 mcg Device - 20 mcg Dose Setting | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 48 |
The record gives a start of Mar 2013, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.